| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pacemaker, Artificial | 26 | 2022 | 55 | 4.520 |
Why?
|
| Arrhythmias, Cardiac | 18 | 2018 | 163 | 3.070 |
Why?
|
| Heart Failure | 33 | 2014 | 232 | 3.030 |
Why?
|
| Cardiac Pacing, Artificial | 20 | 2022 | 146 | 2.810 |
Why?
|
| Defibrillators, Implantable | 18 | 2017 | 45 | 2.360 |
Why?
|
| Cardiology | 12 | 2012 | 47 | 1.380 |
Why?
|
| Evidence-Based Medicine | 14 | 2013 | 140 | 1.280 |
Why?
|
| Cardiac Resynchronization Therapy | 8 | 2017 | 18 | 1.130 |
Why?
|
| Guideline Adherence | 12 | 2012 | 91 | 1.110 |
Why?
|
| Practice Guidelines as Topic | 13 | 2012 | 233 | 1.030 |
Why?
|
| Prospective Studies | 38 | 2022 | 1219 | 0.910 |
Why?
|
| Electric Countershock | 4 | 2017 | 29 | 0.900 |
Why?
|
| Aged | 46 | 2019 | 5169 | 0.880 |
Why?
|
| Equipment Design | 17 | 2022 | 211 | 0.850 |
Why?
|
| Ambulatory Care | 12 | 2012 | 58 | 0.840 |
Why?
|
| Cardiac Catheters | 5 | 2017 | 9 | 0.820 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2013 | 63 | 0.800 |
Why?
|
| Clinical Competence | 4 | 2017 | 204 | 0.800 |
Why?
|
| Male | 56 | 2022 | 12866 | 0.770 |
Why?
|
| Sick Sinus Syndrome | 3 | 2022 | 5 | 0.750 |
Why?
|
| Treatment Outcome | 23 | 2022 | 2267 | 0.740 |
Why?
|
| Registries | 15 | 2019 | 383 | 0.710 |
Why?
|
| Female | 57 | 2022 | 14462 | 0.680 |
Why?
|
| Humans | 76 | 2022 | 26856 | 0.660 |
Why?
|
| Equipment Failure Analysis | 3 | 2017 | 36 | 0.620 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 28 | 0.560 |
Why?
|
| Primary Prevention | 1 | 2017 | 25 | 0.560 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 32 | 0.550 |
Why?
|
| Middle Aged | 36 | 2019 | 6825 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2012 | 160 | 0.470 |
Why?
|
| Atrial Fibrillation | 4 | 2019 | 398 | 0.460 |
Why?
|
| Follow-Up Studies | 16 | 2018 | 981 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 358 | 0.440 |
Why?
|
| Ventricular Fibrillation | 1 | 2013 | 40 | 0.440 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 1927 | 0.430 |
Why?
|
| Catheter Ablation | 3 | 2012 | 220 | 0.430 |
Why?
|
| Atrioventricular Node | 2 | 2012 | 69 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 3 | 2010 | 51 | 0.410 |
Why?
|
| Stroke Volume | 9 | 2017 | 111 | 0.410 |
Why?
|
| Electrocardiography | 7 | 2017 | 391 | 0.400 |
Why?
|
| Quality Improvement | 2 | 2013 | 112 | 0.400 |
Why?
|
| Coronary Disease | 2 | 2008 | 118 | 0.390 |
Why?
|
| Heart Rate | 5 | 2016 | 374 | 0.390 |
Why?
|
| Education, Medical, Continuing | 4 | 2005 | 34 | 0.360 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 3 | 2007 | 96 | 0.360 |
Why?
|
| Risk Factors | 9 | 2022 | 2017 | 0.330 |
Why?
|
| Prosthesis-Related Infections | 2 | 2019 | 12 | 0.330 |
Why?
|
| Heart Conduction System | 4 | 2007 | 270 | 0.320 |
Why?
|
| Quality of Life | 4 | 2022 | 463 | 0.320 |
Why?
|
| United States | 18 | 2017 | 2035 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 4 | 2011 | 62 | 0.310 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 26 | 0.300 |
Why?
|
| Device Removal | 2 | 2019 | 30 | 0.300 |
Why?
|
| Patient Selection | 2 | 2019 | 143 | 0.290 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 57 | 0.290 |
Why?
|
| Outpatients | 7 | 2013 | 42 | 0.290 |
Why?
|
| Time Factors | 9 | 2019 | 1564 | 0.280 |
Why?
|
| Electrophysiology | 4 | 2006 | 150 | 0.280 |
Why?
|
| Prostheses and Implants | 2 | 2021 | 27 | 0.250 |
Why?
|
| Exercise Test | 3 | 2016 | 246 | 0.250 |
Why?
|
| Curriculum | 2 | 2004 | 262 | 0.250 |
Why?
|
| Telemetry | 1 | 2005 | 8 | 0.250 |
Why?
|
| Hypertension | 1 | 2008 | 304 | 0.240 |
Why?
|
| Preventive Health Services | 1 | 2005 | 15 | 0.240 |
Why?
|
| Stroke | 1 | 2008 | 233 | 0.240 |
Why?
|
| Heart Ventricles | 2 | 2019 | 127 | 0.230 |
Why?
|
| Atherosclerosis | 1 | 2005 | 91 | 0.230 |
Why?
|
| Sinoatrial Node | 1 | 2003 | 16 | 0.230 |
Why?
|
| Cohort Studies | 10 | 2019 | 860 | 0.220 |
Why?
|
| Electrodes, Implanted | 4 | 2017 | 40 | 0.220 |
Why?
|
| Heart Transplantation | 1 | 2003 | 42 | 0.220 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 44 | 0.220 |
Why?
|
| Patient Safety | 3 | 2017 | 36 | 0.210 |
Why?
|
| Pericardial Effusion | 1 | 2022 | 12 | 0.210 |
Why?
|
| Survival Rate | 5 | 2017 | 407 | 0.200 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2016 | 117 | 0.200 |
Why?
|
| Ventricular Function, Right | 2 | 2007 | 13 | 0.200 |
Why?
|
| Electronic Health Records | 2 | 2012 | 59 | 0.180 |
Why?
|
| Algorithms | 3 | 2016 | 419 | 0.180 |
Why?
|
| Research Design | 2 | 2015 | 173 | 0.180 |
Why?
|
| Ventricular Pressure | 2 | 2002 | 5 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 400 | 0.170 |
Why?
|
| Prosthesis Design | 2 | 2017 | 82 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2017 | 586 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 346 | 0.170 |
Why?
|
| Endocarditis | 1 | 2019 | 16 | 0.160 |
Why?
|
| Accelerometry | 1 | 2018 | 11 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2017 | 231 | 0.160 |
Why?
|
| Bacteremia | 1 | 2019 | 80 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2010 | 111 | 0.160 |
Why?
|
| Quality of Health Care | 2 | 2010 | 77 | 0.150 |
Why?
|
| Bradycardia | 2 | 2017 | 17 | 0.150 |
Why?
|
| Adult | 12 | 2017 | 7389 | 0.150 |
Why?
|
| Physician Assistants | 2 | 2010 | 10 | 0.150 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 144 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2012 | 342 | 0.150 |
Why?
|
| Cardiac Catheterization | 2 | 1995 | 112 | 0.140 |
Why?
|
| Age Factors | 3 | 2017 | 716 | 0.140 |
Why?
|
| Sex Factors | 4 | 2013 | 445 | 0.140 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2017 | 1 | 0.140 |
Why?
|
| Heart Failure, Systolic | 1 | 2017 | 3 | 0.140 |
Why?
|
| Exercise | 2 | 2018 | 451 | 0.140 |
Why?
|
| Ventricular Function, Left | 4 | 2012 | 100 | 0.140 |
Why?
|
| Phenethylamines | 1 | 2016 | 5 | 0.130 |
Why?
|
| Sotalol | 1 | 2016 | 9 | 0.130 |
Why?
|
| Prognosis | 3 | 2013 | 758 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2012 | 209 | 0.130 |
Why?
|
| Equipment Safety | 1 | 2015 | 18 | 0.130 |
Why?
|
| Inpatients | 1 | 2016 | 56 | 0.130 |
Why?
|
| Decision Making | 1 | 2017 | 169 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2016 | 69 | 0.130 |
Why?
|
| Smartphone | 1 | 2016 | 58 | 0.130 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 8 | 0.130 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1995 | 7 | 0.120 |
Why?
|
| Mobile Applications | 1 | 2016 | 58 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 189 | 0.120 |
Why?
|
| Prevalence | 2 | 2013 | 469 | 0.120 |
Why?
|
| Pulmonary Artery | 1 | 1995 | 68 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 748 | 0.120 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2011 | 4 | 0.110 |
Why?
|
| Monitoring, Ambulatory | 2 | 2005 | 26 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 33 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2011 | 65 | 0.110 |
Why?
|
| African Americans | 2 | 2014 | 348 | 0.110 |
Why?
|
| Hemodynamics | 2 | 2005 | 220 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1993 | 52 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 11 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 509 | 0.100 |
Why?
|
| Hospitalization | 1 | 2012 | 193 | 0.090 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2015 | 14 | 0.090 |
Why?
|
| Advanced Practice Nursing | 1 | 2010 | 2 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 20 | 0.090 |
Why?
|
| Creatinine | 1 | 2010 | 57 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 48 | 0.090 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 22 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 80 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2008 | 89 | 0.080 |
Why?
|
| American Heart Association | 2 | 2008 | 21 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 290 | 0.080 |
Why?
|
| Medical Laboratory Science | 1 | 2008 | 5 | 0.080 |
Why?
|
| Allied Health Personnel | 1 | 2008 | 14 | 0.080 |
Why?
|
| Young Adult | 1 | 2015 | 2584 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 12 | 0.080 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2008 | 3 | 0.080 |
Why?
|
| Cause of Death | 1 | 2008 | 66 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 32 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 87 | 0.070 |
Why?
|
| Defibrillators | 1 | 2007 | 3 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 203 | 0.070 |
Why?
|
| Miniaturization | 2 | 2017 | 10 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 588 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2005 | 171 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2005 | 26 | 0.060 |
Why?
|
| Health Policy | 1 | 2005 | 59 | 0.060 |
Why?
|
| Ohio | 1 | 2004 | 7 | 0.060 |
Why?
|
| Biosensing Techniques | 1 | 2005 | 41 | 0.060 |
Why?
|
| Health Education | 1 | 2005 | 71 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2005 | 40 | 0.060 |
Why?
|
| Certification | 1 | 2004 | 15 | 0.060 |
Why?
|
| Specialty Boards | 1 | 2004 | 10 | 0.060 |
Why?
|
| Competency-Based Education | 1 | 2004 | 16 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2005 | 75 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 297 | 0.060 |
Why?
|
| Coronary Artery Disease | 2 | 1997 | 213 | 0.060 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2003 | 5 | 0.050 |
Why?
|
| Health Promotion | 1 | 2005 | 169 | 0.050 |
Why?
|
| Telemedicine | 1 | 2005 | 135 | 0.050 |
Why?
|
| Troponin I | 1 | 2002 | 14 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2008 | 54 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 447 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2001 | 38 | 0.050 |
Why?
|
| Oklahoma | 1 | 2004 | 971 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2001 | 60 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 206 | 0.050 |
Why?
|
| Myocardium | 1 | 2002 | 171 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 545 | 0.040 |
Why?
|
| Medical Records | 2 | 2012 | 49 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 1997 | 149 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 25 | 0.040 |
Why?
|
| Morbidity | 2 | 2009 | 57 | 0.040 |
Why?
|
| Workload | 1 | 1998 | 38 | 0.040 |
Why?
|
| Europe | 2 | 2008 | 96 | 0.040 |
Why?
|
| Consensus | 2 | 2008 | 69 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 218 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 1997 | 14 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 701 | 0.040 |
Why?
|
| Telephone | 1 | 1997 | 25 | 0.040 |
Why?
|
| Factor VIIa | 1 | 1997 | 29 | 0.040 |
Why?
|
| Differential Threshold | 1 | 2017 | 2 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 21 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 60 | 0.040 |
Why?
|
| Logistic Models | 3 | 2009 | 397 | 0.040 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 2 | 0.030 |
Why?
|
| Materials Testing | 1 | 2016 | 86 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 43 | 0.030 |
Why?
|
| Fibrinogen | 1 | 1996 | 50 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 399 | 0.030 |
Why?
|
| Microelectrodes | 1 | 2015 | 18 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 193 | 0.030 |
Why?
|
| Diastole | 1 | 1995 | 22 | 0.030 |
Why?
|
| Valsalva Maneuver | 1 | 1995 | 8 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 40 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 45 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1995 | 68 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 472 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 496 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 1995 | 187 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 42 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 1993 | 34 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 84 | 0.030 |
Why?
|
| Recurrence | 1 | 1993 | 316 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2011 | 5 | 0.020 |
Why?
|
| Heart Atria | 1 | 1993 | 171 | 0.020 |
Why?
|
| Hiccup | 1 | 1971 | 1 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 264 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 162 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 277 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 80 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1971 | 43 | 0.020 |
Why?
|
| Professional Competence | 1 | 2010 | 36 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2010 | 5 | 0.020 |
Why?
|
| Adolescent | 2 | 1997 | 2960 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2010 | 2444 | 0.020 |
Why?
|
| Echocardiography | 1 | 2010 | 107 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 66 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 68 | 0.020 |
Why?
|
| Professional Role | 1 | 2008 | 42 | 0.020 |
Why?
|
| Benchmarking | 1 | 2007 | 28 | 0.020 |
Why?
|
| Comorbidity | 1 | 2007 | 251 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 802 | 0.020 |
Why?
|
| Pressure | 1 | 2005 | 88 | 0.020 |
Why?
|
| Heart Block | 1 | 1983 | 43 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 1983 | 56 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2002 | 4 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2002 | 13 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 86 | 0.010 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2001 | 23 | 0.010 |
Why?
|
| Goals | 1 | 2001 | 33 | 0.010 |
Why?
|
| Teaching | 1 | 2001 | 76 | 0.010 |
Why?
|
| Dizziness | 1 | 1997 | 10 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1997 | 31 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 125 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1996 | 207 | 0.010 |
Why?
|
| Smoking | 1 | 1996 | 466 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1971 | 368 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1989 | 19 | 0.010 |
Why?
|
| Dogs | 1 | 1989 | 504 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1971 | 848 | 0.000 |
Why?
|
| Procainamide | 1 | 1983 | 9 | 0.000 |
Why?
|
| Disopyramide | 1 | 1983 | 10 | 0.000 |
Why?
|
| Ebstein Anomaly | 1 | 1983 | 10 | 0.000 |
Why?
|
| Endocardium | 1 | 1983 | 16 | 0.000 |
Why?
|
| Propranolol | 1 | 1983 | 38 | 0.000 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1983 | 23 | 0.000 |
Why?
|
| Animals | 1 | 1989 | 9954 | 0.000 |
Why?
|